Premium

Sanofi (SNY): will it succeed in replacing Dupixant?

Pharmaceutical company Sanofi is facing an upcoming patent expiry for its flagship drug, Dupixant, and is working to secure its future through collaborations and potential acquisitions.

By the SpyStocks desk · 2h ago · 4 min read

The rest of this story is for members

The rest is for members

The story continues: the full timeline, the transaction ranges, and the names the forms carry.

Premium comes through the Telegram channel. Already have a code? Sign in to activate it.

Telegram@TheAmericanDream5

Hot stock alerts, straight to Telegram

Real-time buys, sweeps, and trading halts from the desk. Free to join.

Join the channel

Sanofi (SNY): will it succeed in replacing Dupixant?

The rest is for members

Hot stock alerts, straight to Telegram

Related Stories

Oracle: a decision point between AI growth and heavy debt

Oracle: a decision point between AI growth and heavy debt

Ondas: its role in the autonomous warfare of the US military

Ondas: its role in the autonomous warfare of the US military

The war officially enters the era of science fiction

The war officially enters the era of science fiction